XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (22,162,767) $ (3,648,645)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 194,698 63,324
Gain on forgiveness of debt (178,250) (10,000)
Non-cash equity-based compensation expense 13,957,145 828,578
Change in operating assets and liabilities:    
Inventory (549,825)
Prepaid expenses and other assets (795,365) (32,166)
Operating lease liabilities (28,521)
Other assets (161,358)
Royalty obligation (900,000) (375,000)
Accounts payable and accrued expenses 897,256 340,816
Net cash used in operating activities (9,726,987) (2,833,093)
Cash flows from investing activities:    
Investments, available-for-sale (7,441,617)
Purchase of property and equipment (257,907)
Payment of patent costs (137,645) (151,169)
Net cash used in investing activities (7,837,169) (151,169)
Cash flows from financing activities:    
Proceeds from common stock issuance 23,100,000 2,779,464
Placement cost (2,548,000)
Proceeds from exercise of options 390,624
Proceeds from SBA - PPP notes payable 178,235
Proceeds from issuance of convertible notes 50,000
Dividends paid (32,504) (97,655)
Principal repayments of notes payable (202,503)
Net cash provided by financing activities 20,707,617 2,910,044
Increase in cash and cash equivalents, and restricted cash 3,143,461 (74,218)
Cash and cash equivalents at beginning of period 10,426,249 2,308,871
Cash and cash equivalents, and restricted cash at end of period 13,569,710 2,234,653
Supplementary disclosure of non-cash financing activities:    
Preferred stock conversion to common 3,094,134 50,000
Common stock issued pursuant to antidilutive provisions 4,691,022
Cashless exercise of warrants 74,375
 Right-of-use assets and operating lease liabilities 23,621,267
Cash paid during the year for:    
Interest $ 303,957 $ 425,323